BNTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BioNTech SE (BNTX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators and recent price performance suggest a neutral to bearish trend, while the financial performance and insider activity raise concerns. Analysts have mixed views, with recent downgrades and limited near-term catalysts. While the company has long-term potential in oncology, the lack of immediate growth drivers and negative sentiment from insider sales make it prudent to hold off on investing right now.
The MACD is negatively expanding (-1.186), RSI is neutral at 35.321, and moving averages are converging, indicating no strong trend. The stock is trading near its support level (S1: 105.925), with resistance at 110.336. Overall, the technical indicators suggest a neutral to bearish trend.
Goldman Sachs recently upgraded the stock with a price target of $142, citing its strategic position in oncology and potential for long-term growth. Revenue grew by 22.02% YoY in Q3 2025, and gross margin increased to 91.01%, reflecting operational efficiency.
Medine GmbH's sale of 858.21K shares and reduction of its stake by 255.92K shares since January 2026 signals insider bearishness. Net income and EPS have significantly declined (-114.49% and -114.81% YoY, respectively). Analysts from Leerink downgraded the stock to Market Perform, citing limited near-term catalysts. The stock has also dropped 3.31% in the regular market session.
In Q3 2025, revenue increased by 22.02% YoY to $1.52 billion, but net income dropped to -$28.7 million (-114.49% YoY), and EPS fell to -$0.12 (-114.81% YoY). Gross margin improved to 91.01%, up 2.47% YoY, indicating operational efficiency but poor profitability.
Analysts are mixed. Leerink downgraded the stock to Market Perform with a $113 price target, citing limited near-term catalysts. Goldman Sachs upgraded it to Buy with a $142 price target, highlighting long-term oncology potential. Berenberg maintains a Buy rating with a $155 price target.
